Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced that a meeting of its Board of Directors will be held on Thursday, May 14, 2026. The primary agenda for this meeting is to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. Additionally, the Board will consider and recommend a dividend, if any, on equity shares for the financial year ended March 31, 2026. In compliance with SEBI regulations and the company's Insider Trading Code, the Trading Window for designated persons has been closed from April 01, 2026, to May 16, 2026, inclusive, to facilitate the approval process of these financial results.
